Actualités sur Enterprises

25.06.2009 – 18:38
Bristol-Myers Squibb and AstraZeneca
ONGLYZA(TM) (saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes
Paris and London (ots/PRNewswire) - Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (LSE: AZN) today announced that their marketing authorisation application for ONGLYZA(TM) (saxagliptin) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of type 2 diabetes in adults as add-on therapy with metformin, ...
plus
25.06.2009 – 17:47
Microsoft Advertising
Microsoft Corporation and Vivaki/Publicis Groupe Announce Broad Strategic Agreement
Paris and Redmond, Washington (ots/PRNewswire) - - Companies Pursue More Engaging Digital Content, Increased Marketing Performance and Sharply-Defined Audiences Microsoft and Publicis Groupe today announced a broad agreement to closely cooperate on three core objectives enabled by the emergence of the digital media world. Focusing on Content, Performance ...
plus
23.06.2009 – 16:13
MetaQuotes Software Corp
First Step Towards the Revolution in the Market of Management Systems - Release of TeamWox Trial Version
Kazan, Russia (ots/PRNewswire) - Today MetaQuotes Software Corp. released the trial version of the groupware system TeamWox. (http://www.teamwox.com/en/demo/download/) TeamWox belongs to the class of software that allows you to organize the efficient teamwork within a company. Its revolutionary innovations ...
plus
23.06.2009 – 14:18
Abbott Laboratories
Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
Abbott Park, Illinois (ots/PRNewswire) - - Broad Size Matrix of XIENCE PRIME to be Launched in Europe in the Third Quarter Abbott announced today that it has received CE Mark (Conformite Europeenne) for its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of ...
plus
23.06.2009 – 14:18
Agendia B.V.
Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
Huntington Beach, California and Amsterdam (ots/PRNewswire) - - International Expert Panel Recommends Use of Multigene Profiling Assays and Finds Intermediate Scores Lack Clinical Utility Agendia, a world leader in molecular cancer diagnostics, today announced the inclusion of its breast cancer recurrence ...
plus
23.06.2009 – 09:09
Wyeth Europa
New Educational Initiative Urges People With Rheumatoid Arthritis (RA) to Dedicate One Day so That They May Make a Lasting Difference to How They Live With Their Condition
Maidenhead, England (ots/PRNewswire) - - My Day for RA Launches Across Europe Today: A Novel 'Goal-Centred' Patient Programme Recognising that rheumatoid arthritis (RA) can cause deformity, disability and loss of independence without effective management - My Day for RA, a new educational programme, ...
plus
22.06.2009 – 14:09
Atmel Corporation
Atmel Introduces AVR32 Microcontroller Which Lowers Industry's Best Power Consumption by 63%
San Jose, California (ots/PRNewswire) - - picoPower AVR32 AT32UC3L Microcontroller offers less than 0.48 mW/MHz Active and below 100 nA Sleep Mode, and has Embedded Capacitive Touch Peripheral and Event System that Eliminates Interrupt Handling and Guarantees Deterministic Response Time Atmel(R) ...
plus
22.06.2009 – 13:08
Astellas Pharma Europe Limited
NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)
San Mateo, California and Staines, England (ots/PRNewswire) - - Conference Call Today at 9:00am ET - Covers Europe, Middle East and Africa - Includes Licensing Option and Development Funding for NGX-1998 NeurogesX, Inc. (NASDAQ: NGSX) and Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo based Astellas Pharma Inc. announced ...
plus
19.06.2009 – 19:07
Valeo Management Services
Valeo Research Projects for Low-CO2 Vehicles Supported by French Environment Agency ADEME
Paris (ots/PRNewswire) - The French environment agency ADEME is supporting Valeo research projects. Two projects for low-CO2 vehicles, which have received 6 million euros in funding from ADEME, were presented yesterday at the French Sustainable Development Ministry: - Mild hybrid (MHYGALE project) Following the micro hybrid, mild hybridization represents ...
plus
17.06.2009 – 00:06
LeapFrog Investments
LeapFrog Raises US$44 Million for World's First Microinsurance Fund
Luxembourg (ots/PRNewswire) - In a breakthrough for microfinance and alternative investment, the LeapFrog Financial Inclusion Fund announced today that it has raised US$44 million. It is the world's first investment fund focused on microinsurance. The fund aims to invest in businesses that will bring insurance and financial services to 25 million low-income people in Africa and Asia. The capital was raised from ...
plus
16.06.2009 – 09:35
Ketchum Ltd
Ketchum and Pleon to Merge, Creating Global Communications Powerhouse
London (ots/PRNewswire) - In an agreement that marks one of the largest mergers ever in the public relations industry, Ketchum, a leading global public relations firm, and Pleon, Europe's largest strategic communications consultancy, have announced today they will combine operations. The merger creates one of the largest, most geographically diverse ...
plus
15.06.2009 – 21:57
Atmel Corporation
Atmel's AT91SO25 Secure Microcontroller Helps Achieve PCI 2.0 Certification for HomeATM's Safe-T-PIN Internet POS Terminal
San Jose, California (ots/PRNewswire) - Atmel(R) Corporation (Nasdaq: ATML) and HomeATM announced today that the recent Payments Card Industry (PCI) 2.0 certification of HomeATM's Safe-T-PIN(TM) is the result of an efficient collaboration between the two leaders on their markets. HomeATM's Safe-T-PIN, powered ...
plus
15.06.2009 – 11:50
Perimeter Institute for Theoretical Physics
Canada's Perimeter Institute "Quantum to Cosmos" Festival to be On-site, Online and On TV
Waterloo, Ontario (ots/PRNewswire) - For 10 exciting days this October, Canada's Perimeter Institute's 10th anniversary science celebration "Quantum to Cosmos: Ideas for the Future" will take a global audience from the strange subatomic world to the outer frontiers of the universe. Events will take place from October 15 to 25, 2009, commemorating the 10th ...
plus
12.06.2009 – 10:20
Wyeth Pharmaceuticals
Wyeth Presents New Analyses of Data From Three Studies of ENBREL(R) at the European League Against Rheumatism (EULAR) Annual Meeting
Maidenhead, England (ots/PRNewswire) - - Two-year Data From COMET Study in Early Active Moderate-to-Severe Rheumatoid Arthritis Indicated Sustained Halt of Progressive Joint Damage - New Analyses From ASCEND Study in Ankylosing Spondylitis Indicated Improvement in Patients With and Without Peripheral ...
plus
11.06.2009 – 13:07
Wyeth Pharmaceuticals
New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
Collegeville, Pennsylvania (ots/PRNewswire) - New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), has the potential to provide coverage against the 13 most ...
plus
10.06.2009 – 09:10
Zebra Technologies
Zebra Technologies Unveils QuikCard(TM) ID Solution for Fast, Easy Creation of Identification Cards
Bourne End, England (ots/PRNewswire) - - Feature-Rich, Value-Priced Bundle Offers a Complete Card Design and Printing Solution for Small and Medium-Size Organisations Zebra Technologies Europe Limited, a global leader in specialty printing and automatic identification solutions, today announced the launch ...
plus
09.06.2009 – 19:23
Valeo Management Services
Valeo: 2009 Combined Annual General Shareholders' Meeting
Paris (ots/PRNewswire) - Valeo's Combined Annual General Shareholders' Meeting (AGM) was held today under the chairmanship of Pascal Colombani, Chairman of Valeo. The AGM approved the 2008 accounts which were published on February 13, 2009. The presentation of the Group's results for 2008 and the first quarter 2009 provided an opportunity for Jacques Aschenbroich, the new CEO of Valeo, to review the situation of ...
plus
09.06.2009 – 14:14
Atmel Corporation
Atmel Upgrades SAM9261S to Higher-frequency SAM9G10 ARM9-based Embedded Microprocessor
San Jose, California (ots/PRNewswire) - - Free Windows Embedded CE and Linux BSPs Provided to Facilitate Application Development Atmel(R) Corporation (Nasdaq: ATML) announced today the release of its SAM9G10 ARM926EJ-S-based embedded microprocessor. The SAM9G10 is an upgrade to the established SAM9261S embedded microprocessor that pushes the boundaries of ...
plus
08.06.2009 – 18:51
Atmel Corporation
Atmel QTouch Library Now Supports AVR and AVR32 Microcontrollers
San Jose, California (ots/PRNewswire) - Atmel(R) Corporation (Nasdaq: ATML) announced today the new release of the popular Atmel QTouch Library, a royalty free software library providing access to the industry-leading QTouch(TM) technology. Without the need for external devices, the QTouch Library adds capacitive touch capabilities to AVR(R) and AVR32 microcontrollers. The new library consists of pre-compiled and ...
plus
08.06.2009 – 07:05
Excellence in Epilepsy Journalism Award
Final Call for Entries to the 'Excellence in Epilepsy' Journalism Award
Brussels (ots/PRNewswire) - The 'Excellence in Epilepsy' Journalism Award - an initiative of the International Bureau for Epilepsy (IBE) and UCB - invites journalists from around the world to submit stimulating, informed and compelling news and feature stories on epilepsy. The award seeks to increase awareness and improve understanding of epilepsy. The closing ...
plus
06.06.2009 – 17:06
Boehringer Ingelheim
New Data From Boehringer Ingelheim's Ongoing Linagliptin Trial Programme Show Promising Safety and Efficacy Results
Ingelheim, Germany (ots/PRNewswire) - - Results From Linagliptin Study in Type 2 Diabetes Patients Who Were Inadequately Controlled on Metformin Therapy Alone, Presented at Major Diabetes Meeting Study results presented for the first time in the scientific sessions of this year's American Diabetes ...
plus
05.06.2009 – 14:07
Atmel Corporation
Atmel Announces Plug & Play Host-side Cryptographic Authentication IC
San Jose, California (ots/PRNewswire) - - Atmel's Host CryptoAuthentication IC Eliminates the Need for Designers to Understand Complex Cryptographic Protocols and Algorithms Atmel(R) Corporation (Nasdaq: ATML) announced today a "plug-and-play" CryptoAuthentication host-side IC (http://www.atmel.com/products/cryptoauthentication/default.asp)that allows ...
plus
04.06.2009 – 08:06
Wyeth Pharmaceuticals
Enbrel(R) Receives Positive European Recommendations for a New Plaque Psoriasis Treatment Regimen and New Pre-Filled Pen Delivery Device
Maidenhead, England (ots/PRNewswire) - - CHMP Recommends Approval of a Continuous Dosing Regimen Option for Enbrel In Plaque Psoriasis, and a New Pre-Filled Pen Delivery Device Today, Wyeth received positive recommendations from the European Committee for Medicinal Products for Human Use (CHMP) for two ...
plus
03.06.2009 – 23:05
Novartis AG
One-Year Phase III Study Confirms Ilaris(R) Offers Long-Term Remission in Patients With CAPS, a Severe Lifelong Auto-Inflammatory Disease
Basel, Switzerland (ots/PRNewswire) - - Not for US Media - New Ilaris Data in The New England Journal of Medicine Show Rapid Sustained Efficacy in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)(1) - CAPS is a Debilitating Genetic Disorder With Potentially Fatal Complications and Limited ...
plus
03.06.2009 – 16:43
sanofi-aventis Group
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
Paris and Brisbane, California (ots/PRNewswire) - - Data Highlighted in Plenary Session of 2009 American Society of Clinical Oncology Annual Meeting Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial ...
plus
02.06.2009 – 12:10
Tata Communications
Tata Communications Launches Application Performance Visibility Service
Mumbai, India (ots/PRNewswire) - - Global Service Helps Customers Ensure Optimal IT Performance Tata Communications, a leading provider of a new world of communications, today announced the launch of Application Performance Visibility Service, a suite of integrated, end-to-end, network and application performance monitoring service with three-tiered ...
plus
02.06.2009 – 07:06
Roche Pharmaceuticals
IMPACT Study Shows Longer Valcyte Treatment Provides Better Protection Against Cytomegalovirus (CMV) Disease CMV is the Most Serious Viral Infection Affecting Transplant Patients
Basel, Switzerland (ots/PRNewswire) - - For Non-US Media Only New Phase III study results presented for the first time today at the ninth annual American Transplant Congress 2009 (ATC) demonstrate that doubling the duration of preventive therapy ('prophylaxis') with Valcyte (oral valganciclovir), ...
plus
01.06.2009 – 19:07
Atmel Corporation
Atmel Introduces Industry's First ARM Cortex-M3 Flash MCU With On-Chip High Speed USB Device-and-Transceiver
San Jose, California (ots/PRNewswire) - - SAM3U is Code Portable from Atmel's Established ARM7- and ARM9-based MCU Families Atmel(R) Corporation (Nasdaq: ATML) announced today the SAM3U, the industry's first ARM(R) Cortex(TM)-M3 Flash microcontroller integrating high speed (480 Mbps) USB ...
plus
01.06.2009 – 12:36
Roche Pharmaceuticals
Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer
Basel, Switzerland (ots/PRNewswire) - - PLX4032 (R7204) Phase I Results Offer Hope of First Highly Effective Drug in Melanoma Along With Companion Diagnostic - For Non-US Media Only Roche announced today results from a Phase I study with PLX4032 (R7204) a new, highly selective and promising ...
plus
30.05.2009 – 17:05
AstraZeneca GmbH
Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
Orlando, Florida (ots/PRNewswire) - Data from the Phase III ZODIAC(1) study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Results show that the study met its primary endpoint, ...
plus

Précédent49505152535455565758Suivant